Comparison of the current renal staging, progression and response criteria to predict renal survival in <scp>AL</scp> amyloidosis using a <scp>Mayo</scp> cohort
Maria Eleni Drosou(Mayo Clinic), Nelson Leung(WinnMed), David Dingli, Lisa E. Vaughan(Mayo Clinic), Francis K. Buadi, Morie A. Gertz(Medical University of South Carolina), Surbhi Sidana(Palo Alto University), Robert A. Kyle(Mayo Clinic), Shaji Kumar(Mayo Clinic), Ronald S. Go(Mayo Clinic), Prashant Kapoor, Amie Fonder, Camden Lopez(Mayo Clinic), Yi L. Hwa, Stephen J. Russell(University of Minnesota Rochester), Rahma Warsame, S. Vincent Rajkumar(WinnMed), Wilson I. Gonsalves(Mayo Clinic in Arizona), Mustaqeem Siddiqui(Mayo Clinic in Arizona), Taxiarchis Kourelis(Mayo Clinic in Arizona), Martha Q. Lacy(Mayo Clinic), Eli Muchtar(Mayo Clinic), Yi Lin, Suzanne R. Hayman, John A. Lust, Angela Dispenzieri(Mayo Clinic), Miriam Hobbs, M Hasib Sidiqi(Curtin University)
Cited by 13
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k